Expression of Bax, Bcl-2, Waf-1, and PCNA gene products in an immortalized human endothelial cell line undergoing p53-mediated apoptosis

Apoptosis

Volumn 2, Issue 5, 1997, Pages 442-454

  Maxwell, S A ^a,b   Acosta, S A ^a   Tombusch, K ^a   Davis, G E ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b Joe Reynolds Medical Building ^*  (United States)

Author keywords

Apoptosis; Endothelial; p53

Indexed keywords

EID: 0000534848     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026418010549     Document Type: Article

References (47)

1. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Develop 1991; 5: 151-159.
2. Diller I, Kassel J, Nelson GE, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 11: 5772-5781.
3. 1 phase. Proc Natl Acad Sci USA 1992; 89: 9210-9214.
4. Alonigrinstein R, Zanbar I, Alboum I, Goldfinger N, Rotter V. Wild-type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 1993; 8: 3297-3305.
5. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
6. Livingstone SR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
7. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
8. WAF1/CIp1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98: 426-433.
9. Yonish-Rouach E, Grunwald D, Wilder S, et al. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 1993; 13: 1415-1423.
10. Debbas M, White E. Wild-type p53 mediates apoptosis through E1A, which is inhibited by E1B. Genes Develop 1993; 7: 546-554.
11. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852.
12. Gottlieb E, Haffner R, Von Ruden T, Wagner EF, Oren M. Downregulation of wild-type p53 actively interferes with apoptosis of IL-3 dependent hematopoietic cells following IL-3 withdrawal. EMBO J 1994; 13: 1368-1374.
13. Merritt AJ, Potten CS, Kemp CJ, et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54: 614-617.
14. Lane DP. p53, guardian of the human genome. Nature 1992; 358: 15-16.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein, B, Craig R. Participation of the p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
16. Zhan Z, Carrier F, Fornac AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993; 13: 4242-4250.
17. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancer. Science 1991; 253: 49-53.
18. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996; 56: 1374-1381.
19. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of the p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562.
20. Gjerset RA, Turla ST, Sobol RE, et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinogen 1995; 14: 275-285.
21. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994; 54: 3718-3722.
22. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995; 7: 547-553.
23. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-1048.
24. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249: 1049-1051.
25. Funk WD, Pak DJ, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992; 12: 2866-2871.
26. El-Deiry WS, Tokino T, Velculescu VE, at al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
27. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of Gi cyclin-dependent kinases. Cell 1993; 75: 805-816.
28. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995; 375: 159-161.
29. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
30. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-1380.
31. Myashita TS, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
32. Miyashita TS, Harigari M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-3135.
33. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
34. Takahashi K, Sawasaki Y, Hat J-I, Mukai K, Goto T. Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev Biol 1990; 25: 265-274.
35. Zhang W-W, Fang X, Branch CD, Mazur W, French BA, Roth JA. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechiniques 1993; 15: 868-872.
36. Maxwell SA, Zhang W-W. Cell type-specific regulation of p53 expression in non-small cell lung carcinoma cells. Oncol Repts 1995; 2: 81-87.
37. Wyllie AH, Kerr JFR, Currie AR. Cell death the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
38. Jackson P, Ridgway P, Rayner J, Noble J, Braithwaite. Transcriptional regulation of the PCNA promoter by p53. Biochem Biophys Res Commm 1994; 203: 133-140.
39. Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1995; 15: 6785-6793.
40. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 1996; 93: 895-899.
41. Yamaguchi M, Hayashi Y, Matsuoka S, Takahashi T, Matsukage A. Differential effect of p53 on the promoters of mouse DNA polymerase β gene and proliferating-cell-nuclear-antigen gene. Eur J Biochem 1994; 221: 227-237.
42. Fairman MP. DNA polymerase δ and PCNA: actions and interactions. J. Cell Sci 1990; 95: 1-4.
43. Tsurimoto T, Melendy T, Stillman B. Sequential initiation of lagging and leading strand synthesis by two different polymerase complexes at the SV40 DNA replication origin Nature 1990; 346: 534-539.
44. Oltavai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
45. Croce CM, Erikson J, Tsujimoto Y, Nowell PC. Molecular basis of human B and T cell neoplasia. In: Klein G, ed. Advances in Viral Oncology. New York, NY (USA): Raven Press, 1987: 35-51.
46. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. JNCI 1994; 86: 499-504.
47. Ogden GR. Bcl-2 overexpression and smoking history in head and neck cancer. JNCI 1996; 88: 1864-1865.